🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

UPDATE 1-Australia reports first blood clot death 'likely' linked to AstraZeneca vaccine

Published 16/04/2021, 10:48 pm
© Reuters.
AZN
-
PFE
-
AZN
-

(Adds details of case, comment from regulator)

By Swati Pandey

SYDNEY, April 16 (Reuters) - Australia on Friday reported its first fatality from blood clots in a recipient of AstraZeneca (NASDAQ:AZN)'s AZN.L COVID-19 shot, and its regulator said there was a likely link between the 48-year-old woman's death and the vaccine.

Hers was the third instance of the rare blood clots appearing in people who have been administered the vaccine in Australia. The other two are recovering well, the Therapeutic Goods Administration (TGA) added.

It said it was "carefully reviewing" similar instances in Australia.

The New South Wales woman received the AstraZeneca vaccine on April 8, the day that the government announced that the Pfizer (NYSE:PFE) PFE.N vaccine would be given as a preference to patients under 50, delaying its inoculation timetable. the absence of an alternative cause for the clot that she developed, Australia's Vaccine Safety Investigation Group (VSIG) "believed that a causative link to vaccination should be assumed at this time," the TGA said.

The VSIG had held a meeting late on Friday following news of the woman's death.

The TGA said her case had been complicated by underlying medical conditions, including diabetes, "as well as some atypical features."

There had been at least 885,000 doses of the AstraZeneca vaccines administered in Australia so far, equating to a frequency of instance of blood clot in every 295,000 cases, the TGA said.

"The overall number ...so far has been no higher than the expected background rate for the more common type of blood clots," it said.

The UK regulator, the Medicines and Healthcare Products Regulatory Agency, has concluded from its review of cases reported in the UK that the overall risk of cerebral venous sinus thrombosis - a rare blood clot in the brain - was approximately 1 in 250,000 who receive the vaccine.

Australia has reported over 22,000 COVID-19 cases of community transmission and 909 deaths. Interactive graphic tracking global spread of coronavirus

https://graphics.reuters.com/world-coronavirus-tracker-and-maps/ Global vaccination tracker

https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.